In this study, we aimed to identify new drug candidates for treating EGFR TKI-resistant lung cancer cells by employing the popular and efficient strategy of drug repurposing, given that new drug development and approval is often protracted and drug attrition rate is notoriously high. Here, EGFR is linked to lung carcinoma.